Indapamide Price in Australia (2026)
Cheapest 2.5 mg tablet: Dapa-Tabs, A$4.00 for 90 tablets. Official PBS price list, Oct 2026.
≈ $0.031 per tabletWhat a patient pays for indapamide in Australia
Most a general patient pays per PBS prescription (A$7.70 with a concession card). If the medicine costs the pharmacy less than this, you pay the lower dispensed price.
5 different brand names across 2 strengths are on the official list.
How much will Indapamide 2.5 mg tablet cost you?
All 5 indapamide products in Australia
| Product | Strength and form | Pack | Price | Per unit |
|---|---|---|---|---|
| Dapa-Tabs | Tablet containing indapamide hemihydrate 2.5 mg | 90 tablets | A$4.00 | A$0.044 |
| Insig | Tablet containing indapamide hemihydrate 2.5 mg | 90 tablets | A$4.00 | A$0.044 |
| APO-Indapamide SR | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | 90 | A$5.07 | A$0.056 |
| Natrilix SR original | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | 90 | A$5.07 | A$0.056 |
| Odaplix SR | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | 90 | A$5.07 | A$0.056 |
Indapamide 2.5 mg tablet: Australia vs 3 other countries
| Country | Price type | Per tablet (local) | Per unit (USD) |
|---|---|---|---|
| South Africa | Single Exit Price (SEP) | R0.63 | $0.038 |
| United States | NADAC pharmacy acquisition cost | $0.11 | $0.11 |
| United Kingdom | NHS Drug Tariff price | £0.10 | $0.14 |
Countries publish different kinds of price (manufacturer, reimbursement or retail), so differences are partly due to what is measured. Converted at ECB reference rates of 23 October 2026.
How PBS prices work in Australia
Prices on this page are the approved ex-manufacturer price on the Pharmaceutical Benefits Scheme (PBS): what the Australian Government has agreed to pay the supplier for the pack. Pharmacy mark-up and dispensing fees are added on top. Patients with a PBS prescription do not pay this price; they pay a government-capped co-payment (lower for concession card holders), and the PBS covers the rest.
Combinations containing indapamide in Australia
Every strength and form of indapamide in Australia
| Strength and form | Products | Cheapest pack | Cheapest per unit |
|---|---|---|---|
| 1.5 mg modified-release tablet | 3 | A$5.07 | A$0.056 |
| 2.5 mg tablet | 2 | A$4.00 | A$0.044 |
Different strengths and forms (for example slow-release or dissolving tablets) are not interchangeable without your doctor's advice.
Other medicine prices in Australia
- Inclisiran price1 productfrom A$1,699
- Incobotulinumtoxina price1 productfrom A$318
- Indacaterol price2 productsfrom A$42.70
- Indacaterol and Mometasone price3 productsfrom A$22.80
- Indapamide and Perindopril price8 productsfrom A$2.50
- Indometacin price3 productsfrom A$4.53
- Infliximab price7 productsfrom A$158
- Inotuzumab Ozogamicin price1 productfrom A$12,454
What people check next
Frequently asked questions
How much does indapamide cost in Australia?
What kind of price is this?
How much will I pay for indapamide at a pharmacy in Australia?
What is the cheapest indapamide 2.5 mg tablet in Australia?
Is indapamide cheaper in other countries?
Sources
- Australian Government Department of Health, Disability and Ageing. Pharmaceutical Benefits Scheme (PBS) Schedule, 1 October 2026 (PBS API). www.pbs.gov.au/. Retrieved 25 October 2026.
- Australian Government Department of Health, Disability and Ageing (PBS). PBS patient co-payments from 1 January 2026: general A$25.00, concessional A$7.70 per script; Safety Net A$1,748.20 / A$277.20. pbs.gov.au/about/what-is-the-pbs/what-are-the-current-patient-fees-and. Retrieved 25 October 2026.
- European Central Bank. Euro foreign exchange reference rates (2026-10-23). www.ecb.europa.eu/stats/eurofxref/eurofxref-daily.xml. Retrieved 25 October 2026.
Important: These are published reference prices and estimates, not a quote, and not medical advice. Actual costs depend on the hospital, your health, the exact treatment and your insurance. Always confirm the price with the provider before treatment. Read our disclaimer · Report an error